Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9221-9228

  Johnson, Jay E ^a   Gettings, Edward J ^b   Schwalm, Jaclyn ^b   Pei, Jianming ^b   Testa, Joseph R ^b   Litwin, Samuel ^b   Von Mehren, Margaret ^b   Broccoli, Dominique ^a  

^a MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TELOMERASE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME 12Q; CHROMOSOME 1Q; CHROMOSOME DELETION; DNA FINGERPRINTING; DNA MICROARRAY; GENE AMPLIFICATION; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; LIPOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; SENESCENCE; TELOMERE;

AGED; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; LIPOSARCOMA; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; TELOMERE;

EID: 35148815673     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1133     Document Type: Article

References (38)

1. Ferreira MG, Miller KM, Cooper JP. Indecent exposure: when telomeres become uncapped. Mol Cell 2004;13:7-18.
2. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-8.
3. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003;13:1549-56.
4. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999;283:1321-5.
5. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998;92:401-13.
6. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-38.
7. Artandi SE, DePinho RA. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 2000;10:39-46.
8. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-52.
9. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279-82.
10. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene 2002;21:564-79.
11. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14:4240-8.
12. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997;3:1271-4.
13. Yeager T, Neumann A, Englezou A, Huschtscha L, Noble J, Reddel R. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999;59:4175-9.
14. 2/M phase of the cell cycle. J Cell Sci 2000;113:4577-85.
15. 2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J Biol Chem 2000;275:30618-22.
16. Murnane JP, Sabatier L, Marder BA, Morgan WF. Telomere dynamics in an immortal human cell line. EMBO J 1994;13:4953-62.
17. Bailey SM, Brenneman MA, Goodwin EH. Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells. Nucleic Acids Res 2004;32:3743-51.
18. Bechter OE, Zou Y, Walker W, Wright WE, Shay JW. Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res 2004;64:3444-51.
19. Londono-Vallejo JA, Der-Sarkissian H, Cazes L, Bacchetti S, Reddel RR. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res 2004;64:2324-7.
20. Le S, Moore JK, Haber JE, Greider CW. RAD50 and RAD51 define two pathways that collaborate to maintain telomeres in the absence of telomerase. Genetics 1999;152:143-52.
21. Lundblad V, Blackburn EH. An alternative pathway for yeast telomere maintenance rescues est1 - senescence. Cell 1993;73:347-60.
22. Teng SC, Zakian VA. Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol Cell Biol 1999;19:8083-93.
23. Chin K, de Solorzano CO, Knowles D, et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004;36:984-8.
24. Johnson JE, Varkonyi RJ, Schwalm J, et al. Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin Cancer Res 2005;11:5347-55.
25. Broccoli D, Godley LA, Donehower LA, Varmus HE, de Lange T. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol 1996;16:3765-72.
26. Keith WN, Hoare SF. Detection of telomerase hTERT gene expression and its splice variants by RT-PCR. Methods Mol Med 2004;97:297-309.
27. Grobelny JV, Kulp-McEliece M, Broccoli D. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening to telomeres (ALT) pathway. Hum Mol Genet 2001;10:1953-61.
28. Grant JD, Broccoli D, Muquit M, Manion FJ, Tisdall J, Ochs MF. Telometric: a tool providing simplified, reproducible measurements of telomeric DNA from constant field agarose gels. Biotechniques 2001;31:1314-6, 8.
29. Pei J, Kruger WD, Testa JR. High-resolution analysis of 9p loss in human cancer cells using single nucleotide polymorphism-based mapping arrays. Cancer Genet Cytogenet 2006;170:65-8.
30. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006;444:444-54.
31. Costa A, Daidone MG, Daprai L, et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006;66:8918-24.
32. Brennan M, Singer S, Maki R, O'Sullivan B. Sarcomas of the soft tissues and bone. In: De Vita V, Hellman S, Rosenberg S, editors. Cancer: principles & practice of oncology. Philadelphia (PA): Lippincott Williams & Wilkins; 2005. p. 1581-686.
33. Rieske P, Bartkowiak JK, Szadowska AM, Olborski B, Harezga-Bal B, Debiec-Rychter M. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. J Exp Clin Cancer Res 1999;18:403-16.
34. Razak ZR, Varkonyi RJ, Kulp-McEliece M, et al. p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance. Mol Cell Biol 2004;24:5967-77.
35. Matthews P, Jones CJ, Skinner J, Haughton M, de Micco C, Wynford-Thomas D. Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. J Pathol 2001;194:183-93.
36. Hellman A, Zlotorynski E, Scherer SW, et al. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 2002;1:89-97.
37. Richards RI. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet 2001;17:339-45.
38. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-23.